How effective is capmatinib?

Capmatinibis approved by the U.S. Food and Drug Administration for the treatment of adult patients with metastatic non-small cell lung cancer who have a specific mutation (METexon14 skipped) detected by a U.S. Food and Drug Administration-approved test. Capmatinibcan be used in treatment-naïve or previously treated patients. The recommended dose of capmatinib is 400 mg taken orally twice daily. When taking, swallow the tablets whole and do not break, chew, or crush them.

In the Phase 2 study, the drug’s overall response rate (ORR) capmatinib in 60 patients who had never Non-small cell lung cancer (NSCLC) occurred in 68% of participants who had received any treatment, and the duration of response was 16.6 months in half of the patients. Close to 70% of people (68%) had their tumors shrink or disappear, which is the overall response rate. Among responders, 5%had a complete response and 63%had a partial response. The median duration of response to capmatinib was 16.6 months (half of the responses were more than 16.6 months and half were less than 16.6 months).

In another study of patients who had previously received cancer treatment for non-small cell lung cancer, 44% of people (more than 10 people4 people) had a partial response to capmatinib and none had a complete response, The median duration of response to capmatinibin this patient group was 9.7 months. There are generic drugs that are officially on the market in Laos, and each box costs about 3 about 3,000. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0